Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

8,990 public trials 1,836 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Completed

Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma

NCT00660231

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Leeds Cancer Centre at St. James's University Hospital Leeds, England, United Kingdom
  • Saint Bartholomew's Hospital London, England, United Kingdom
  • St. Thomas' Hospital London, England, United Kingdom
  • Christie Hospital Manchester, England, United Kingdom
View Trial Details
Completed

AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia

NCT01431664

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Royal Marsden Hospital Surrey, London, United Kingdom
  • Birmingham Children's Hospital Birmingham, United Kingdom
  • Leeds General Infirmary Leeds, United Kingdom
  • Royal Manchester Children's Hospital Manchester, United Kingdom
View Trial Details
Completed

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

NCT01561911

Conditions
B-Cell, Cancer, Hemic and Lymphatic Diseases, +8 more
Locations
  • Cancer Research UK Institute for Cancer Studies, University of Birmingham Edgbaston, Birmingham, United Kingdom
  • Cancer Research UK Medical Oncology Unit, Southampton General Hospital Tremona Road,, Southampton, United Kingdom
View Trial Details
Completed

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT01470456

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Investigational Site Number 040002 Graz, Austria
  • Investigational Site Number 250004 Créteil, France
  • Investigational Site Number 250009 Dijon, France
  • Investigational Site Number 250006 Lille, France
View all 13 locations
View Trial Details
Completed

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT00513955

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Basingstoke and North Hampshire NHS Foundation Trust Basingstoke, England, United Kingdom
  • Good Hope Hospital Birmingham, England, United Kingdom
  • Birmingham Heartlands Hospital Birmingham, England, United Kingdom
  • Blackpool Victoria Hospital Blackpool, England, United Kingdom
View all 25 locations
View Trial Details
Completed

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

NCT00891839

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Teva Investigational Site 11 Fountain Valley, California, United States
  • Teva Investigational Site 2 Los Angeles, California, United States
  • Teva Investigational Site 35 Orlando, Florida, United States
  • Teva Investigational Site 30 Lafayette, Indiana, United States
View all 13 locations
View Trial Details

Related conditions